Dizal has reported positive safety and pharmacokinetic findings from the Phase I clinical trial of DZD1516 in HER2 positive metastatic breast cancer (HER2+ MBC) patients who relapsed, following multiple previous therapies.

The global trial enrolled HER2+ MBC patients who have relapsed from, or were not tolerant to, the standard of care (SoC). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Assessing the safety of DZD1516 and detecting the maximum tolerated dose (MTD) was the trial’s primary goal.

By 20 February this year, DZD1516 was analysed in 22 subjects with HER2+ MBC in the US and China, of which approximately 70% had CNS metastases at baseline. 

According to the latest findings, DZD1516 was found to be well tolerated at doses ≤250mg, and in line with its greater selectivity.

In the trial, no wild-type, EGFR-related adverse events (AEs) were seen. 

A 250mg dose of DZD1516 was therefore selected as the MTD.

In trial subjects, mean Kpuu, CSF was found to be 2.1 for DZD1516 across various dose ranges, showing complete penetration of the therapy through the human blood-brain barrier (BBB).

In the trial, 18 subjects concluded ≥1 post-treatment RECIST analysis. 

The best antitumor efficacy in intracranial, extracranial, and complete lesions was stable disease with a median of seven previous lines of systemic therapy.

DZD1516 is an oral, reversible, selective and complete BBB-penetrant HER2 tyrosine kinase inhibitor (TKI).

As against wild-type EGFR, it is said to have over 300-fold selectivity for HER2. 

Nearly 60% of advanced HER2-positive breast cancer patients develop brain metastasis, with a poor prognosis. 

Dizal CEO Dr Xiaolin Zhang said: “Patients with HER2 positive breast cancer and brain metastasis have poor outcomes due to the limited therapies.

“Based on these promising findings, we will further explore the potential of DZD1516 as a new treatment option for this underserved patient population.”